Royal Bank Of Canada Bellus Health Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $73,606 - $87,935	10,309 Added 5.13%	211,076 $1.52 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $1.34 Million - $1.75 Million	163,059 Added 432.43%	200,767 $1.65 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $66,337 - $88,944	-7,412 Reduced 16.43%	37,708 $398,000
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $56,944 - $88,326	-8,815 Reduced 16.34%	45,120 $416,000
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $111,477 - $160,199	20,050 Added 59.17%	53,935 $371,000
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $121,106 - $191,099	23,024 Added 211.99%	33,885 $273,000
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $11,682 - $28,731	4,327 Added 66.22%	10,861 $67,000
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.61 $20,320 - $30,121	6,534 New	6,534 $20,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.